Pharmacogenetics studies in stroke patients treated with rtPA: a review of the most interesting findings / Laia Llucià-Carol, Elena Muiño, Cristina Gallego-Fabrega, Jara Cárcel-Márquez, Jesus Martín-Campos, Miquel Lledós, Natalia Cullell, Israel Fernández-Cadenas
Recombinant tissue-plasminogen activator (rtPA) is the only drug used during the acute phase of stroke. Despite its important benefits, a percentage of patients suffer symptomatic hemorrhagic transformations or a lack of early recanalization rates. These undesirable effects are associated with acute neurological and long-term functional deterioration. For the past 20 years, pharmacogenetic studies have tried to find the genetic risk factors associated with rtPA response. Most of these studies have used a gene-candidate strategy; however, recent genome-wide association studies have emerged indicating that genetic predisposition could modulate rtPA response. This review summarizes the most interesting findings in this field, including which genes and genetic variations are associated with hemorrhagic transformations and recanalization rates after thrombolytic therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2021 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Llucià-Carol, Laia [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Umfang: |
1 Online-Ressource (7 p) |
|---|
| doi: |
10.2217/pgs-2021-0100 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011091193 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011091193 | ||
| 003 | DE-627 | ||
| 005 | 20231109205957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2021-0100 |2 doi | |
| 035 | |a (DE-627)KFL011091193 | ||
| 035 | |a (KFL)prod_FICIBQ_10.2217/pgs-2021-0100 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Llucià-Carol, Laia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacogenetics studies in stroke patients treated with rtPA: a review of the most interesting findings |c Laia Llucià-Carol, Elena Muiño, Cristina Gallego-Fabrega, Jara Cárcel-Márquez, Jesus Martín-Campos, Miquel Lledós, Natalia Cullell, Israel Fernández-Cadenas |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2021 | |
| 300 | |a 1 Online-Ressource (7 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Recombinant tissue-plasminogen activator (rtPA) is the only drug used during the acute phase of stroke. Despite its important benefits, a percentage of patients suffer symptomatic hemorrhagic transformations or a lack of early recanalization rates. These undesirable effects are associated with acute neurological and long-term functional deterioration. For the past 20 years, pharmacogenetic studies have tried to find the genetic risk factors associated with rtPA response. Most of these studies have used a gene-candidate strategy; however, recent genome-wide association studies have emerged indicating that genetic predisposition could modulate rtPA response. This review summarizes the most interesting findings in this field, including which genes and genetic variations are associated with hemorrhagic transformations and recanalization rates after thrombolytic therapy | ||
| 653 | |a genetics | ||
| 653 | |a hemorrhagic transformation | ||
| 653 | |a rtPA | ||
| 653 | |a stroke | ||
| 700 | 1 | |a Muiño, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego-Fabrega, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Cárcel-Márquez, Jara |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Campos, Jesus |e verfasserin |4 aut | |
| 700 | 1 | |a Lledós, Miquel |e verfasserin |4 aut | |
| 700 | 1 | |a Cullell, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Cadenas, Israel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d London [u.a.] : Ashley, 2000 |h Online-Ressource |w (DE-627)KFL00000605X |w (DE-600)2030168-6 |w (DE-576)398099871 |x 1744-8042 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.2217/pgs-2021-0100 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||